ACAD
34.83
+0.38
+1.10%
AEMD
3.35
-0.4
-10.67%
APRI
2.25
-0.04
-1.75%
ARNA
1.46
+0.01
+0.69%
ATEC
2.19
+0.12
+5.80%
CNAT
4.82
+0.23
+5.01%
CRXM
0.2
0.00
0.00%
CYTX
1.65
+0.01
+0.61%
DXCM
82.62
+6.54
+8.60%
GNMK
13.4
+0.26
+1.98%
HALO
13.53
+0.07
+0.52%
ILMN
170.58
+2.89
+1.72%
INNV
0.11
0.00
+4.08%
INO
6.05
+0.1
+1.68%
ISCO
1.78
+0.13
+7.88%
ISIS
57.56
0.00
0.00%
LGND
104.78
+0.99
+0.95%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
-0.24
-9.56%
MEIP
1.54
-0.03
-1.91%
MNOV
5.87
+0.06
+1.03%
MRTX
5.15
+0.05
+0.98%
MSTX
0.114
+0.007
+6.542%
NBIX
41.98
+0.48
+1.16%
NUVA
74.85
+0.56
+0.75%
ONCS
1.27
+0.02
+1.60%
ONVO
3.03
+0.02
+0.66%
OREX
3.98
-0.02
-0.50%
OTIC
12.85
-0.25
-1.91%
QDEL
21.84
+0.17
+0.76%
RCPT
231.96
0.00
0.00%
RGLS
1.4
+0.15
+12.00%
RMD
71.57
+0.26
+0.36%
SPHS
2.87
+0.29
+11.24%
SRNE
4.1
-0.1
-2.38%
TROV
1
-0.15
-13.04%
VICL
2.15
+0.02
+0.94%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.05
+0.48%
ACAD
34.83
+0.38
+1.10%
AEMD
3.35
-0.4
-10.67%
APRI
2.25
-0.04
-1.75%
ARNA
1.46
+0.01
+0.69%
ATEC
2.19
+0.12
+5.80%
CNAT
4.82
+0.23
+5.01%
CRXM
0.2
0.00
0.00%
CYTX
1.65
+0.01
+0.61%
DXCM
82.62
+6.54
+8.60%
GNMK
13.4
+0.26
+1.98%
HALO
13.53
+0.07
+0.52%
ILMN
170.58
+2.89
+1.72%
INNV
0.11
0.00
+4.08%
INO
6.05
+0.1
+1.68%
ISCO
1.78
+0.13
+7.88%
ISIS
57.56
0.00
0.00%
LGND
104.78
+0.99
+0.95%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
-0.24
-9.56%
MEIP
1.54
-0.03
-1.91%
MNOV
5.87
+0.06
+1.03%
MRTX
5.15
+0.05
+0.98%
MSTX
0.114
+0.007
+6.542%
NBIX
41.98
+0.48
+1.16%
NUVA
74.85
+0.56
+0.75%
ONCS
1.27
+0.02
+1.60%
ONVO
3.03
+0.02
+0.66%
OREX
3.98
-0.02
-0.50%
OTIC
12.85
-0.25
-1.91%
QDEL
21.84
+0.17
+0.76%
RCPT
231.96
0.00
0.00%
RGLS
1.4
+0.15
+12.00%
RMD
71.57
+0.26
+0.36%
SPHS
2.87
+0.29
+11.24%
SRNE
4.1
-0.1
-2.38%
TROV
1
-0.15
-13.04%
VICL
2.15
+0.02
+0.94%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.05
+0.48%
Home » Archive by Category

Syndication

Product Manager – Retrophin – San Diego, CA

January 18, 2017 – 10:13 am

Assist Marketing and Patient Care departments inthe implementation and support of any patient initiatives….From Retrophin – Wed, 18 Jan 2017 18:13:29 GMT – View all San Diego jobs

Product Manager – Retrophin – San Diego, CA

January 18, 2017 – 10:13 am

Assist Marketing and Patient Care departments inthe implementation and support of any patient initiatives….From Retrophin – Wed, 18 Jan 2017 18:13:29 GMT – View all San Diego jobs

Boston Biomedical to Highlight Data for Cancer Stemness Inhibitor Napabucasin in Patients with Colorectal Cancer at 2017 ASCO GI

January 18, 2017 – 9:47 am

CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ — Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, will feature data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in San Francisco.

Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3.i Cancer stem cells (CSCs) possess the property of stemness – the ability to self-renew and differentiate into heterogeneous cancer cells. This allows the CSCs to act like seeds, causing a patient’s cancer to relapse or spread within the body.ii,iii In preclinical studies, the STAT3 pathway was identified as an important pathway for maintaining cancer stemness.

Data from the two studies will be presented as poster presentations on January 21. The studies evaluate anti-cancer activity of napabucasin in combination with FOLFIRI with and without bevacizumab in patients with metastatic colorectal cancer (CRC), including treatment-naïve patients and patients previously exposed to FOLFIRI regardless of pSTAT3 status, and safety and anti-cancer activity of napabucasin in combination with panitumumab in patients with K-ras wild type metastatic colorectal cancer (mCRC).

Planned data posters include:

Saturday, January 21, from 7:00 AM7:55 AM and 12:30 PM2:00 PM PST; Moscone West Building

  • Abstract #593: Cancer Stemness Inhibition and Chemosensitization: Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (bev) administered to colorectal cancer (CRC) patients (pts)
    • Bendell J1, O’Neil BH2, Starodub A3, Jonker D4, Halfdanarson TR5, Edenfield J6, El-Rayes, B7, Hubbard J8, Pitot H8, Hobday T8, Li Y-Z9, Gao Y9, Grothey A8, Borodyansky L9, and Li CJ9
    • 1. Sarah Cannon Cancer Research Program, Nashville, TN; 2. IU Health University Hospital, Indianapolis, IN; 3. IU Goshen Health Center, Goshen, IN; 4. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; 5. Mayo Clinic, Scottsdale, AZ; 6. Institute for Translational Oncology Research, Greenville, SC; 7. The Winship Cancer Institute of Emory University, Atlanta, GA; 8. Mayo Clinic, Rochester, MN; 9. Boston Biomedical, Inc., Cambridge, MA.
  • Abstract #677: BBI608-224: A Phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in K-ras wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC)
    • Larson TG1, Ciombor K2, Becerra CHR1, Hubbard JM3, Edenfield WJ4, Shao S5, Grothey A3, Walsh E7, Borodyansky L7, Ortuzar W7, Khan W7, Xu B7, Li W1, Li Y7, Li CJ7 and Bekaii-Saab T6
    • 1. US Oncology Research, TOPS Phase I Program; 2. Ohio State University Wexner Medical Center, Columbus, OH; 3. Mayo Clinic, Rochester, MN; 4. Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC; 5. Northwest Cancer Specialist, Portland OR; 6. Mayo Clinic, Scottsdale AZ; 7. Boston Biomedical, Inc., Cambridge, MA

About Napabucasin

Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3.i

Napabucasin is currently being investigated in multiple Phase III studies, including gastric and gastroesophageal junction (GEJ) (NCT02178956), colorectal (NCT02753127) and pancreatic cancer (NCT0299373). It is also being investigated in earlier phases in multiple solid and hematologic malignancies, including tumors of the lung, liver, pancreas and brain. In 2016, the U.S. Food and Drug Administration granted Orphan Drug Designation for napabucasin in gastric/GEJ and pancreatic cancer.

More information on napabucasin and ongoing clinical trials can be found at www.BostonBiomedical.com.

About Boston Biomedical

Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November 2006 and is wholly owned by Sumitomo Dainippon Pharma Co., Ltd. Boston Biomedical’s mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stemness pathways. Boston Biomedical’s innovation in drug discovery has received a number of recognitions and awards in the United States, including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute (NCI) cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the “Company To Watch” award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.

Additional information about the company and its product pipeline can be found at www.BostonBiomedical.com.

Disclaimer Regarding Forward-Looking Statements

The forward-looking statements in this press release are based on management’s assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

For general inquiries: 
Boston Biomedical  
617-674-6800 

For media inquiries:  
Sara Baker 
CHAMBERLAIN PR 
212- 849-9474 
sara.baker@inventivhealth.com

i Li Y, Rogoff HA et al. PNAS. 112(6):1839-44, 2015.
ii Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010-1012.
iii Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015;42(suppl 1):S3-S17.

SOURCE Boston Biomedical Pharma, Inc.

Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study

January 18, 2017 – 9:00 am

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ — Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the first patient with its lead compound DMT210, in a Phase 2 acne rosacea study. DMT210 is a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.

This clinical trial, DMT210-003, is a 12-week, Phase 2, multi-center, double-blind, vehicle controlled study designed to evaluate the safety, tolerability and efficacy of twice daily dosing of DMT210 in approximately 104 moderate to severe acne rosacea patients. Dermata expects to have top line results in the second half of 2017.

“Based on the clinical response observed in our 28-day Phase 1 study in rosacea patients, we believe this Phase 2 rosacea study will further elucidate the anti-inflammatory and anti-redness properties of DMT210,” states Chris Nardo, VP, Development of Dermata. “Working upstream and downstream in the skin’s inflammatory process, DMT210 blocks TLR-2 and GPCR (G-protein coupled receptor) signaling, thus potentially inhibiting the IL-6, IL-8 and TNF-a expression in skin of rosacea patients. Unlike other currently marketed rosacea products, DMT210 has the potential to reduce inflammatory lesions as well as the redness associated with rosacea.”

About Rosacea: Rosacea is a chronic, inflammatory skin disorder of the facial region that is estimated to affect 13 to 14 million individuals in the United States. Rosacea’s onset typically begins around age 30 and gets progressively worse if left untreated. The disease is characterized by erythema (redness), telangiectasia, flushing, papules, pustules, ocular redness, and rhinophyma.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.

CONTACT:

Dermata Contact

Sean Proehl

Investor Relations

858.223.0882

sgproehl@dermatarx.com

 

SOURCE Dermata Therapeutics, LLC

Social Media & SEO Sales / Start January 30th – $50,000-$100,000/yr (San Diego)

January 18, 2017 – 7:40 am

17-year-old Digital Marketing company that provides Social Media, Web Marketing, SEO and other online marketing solutions to businesses throughout the USA. We love to hire recent college grads with a passion and a burning desire to jump-start their c […

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

January 18, 2017 – 5:05 am

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ — HUYA Bioscience International, (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA is the first company to have recognized China’s potential as an important source of new innovative preclinical and clinical stage compounds. The company accelerates development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. In keeping with this strategic vision, HUYA has already established over one hundred collaborations with leading universities, research institutes, and science parks throughout China.

CAS Innovation is wholly owned by the Chinese Academy of Sciences. It is building a comprehensive platform for transforming and commercializing scientific and technological achievements, and fostering international collaborations. CAS Innovation has selected biomedicine as one of its core areas, positioning itself as a base for biopharmaceutical translational medicine, and targeting innovative R&D in the high-end segment of the industry value chain in order to push forward industrialization of China’s most innovative drugs.

Under this agreement, HUYA and CAS Innovation will collaborate to develop novel drugs discovered by CAS scientists. Biotech and pharmaceutical R&D organizations within the CAS Innovation platform will have access to HUYA’s international pharmaceutical expertise and networks as well as support from HUYA’s global team of experts. In turn, HUYA will have priority to evaluate certain research and development projects conducted by these CAS organizations and secure partnerships to further develop and commercialize these candidate therapeutics for global markets.

“The Chinese Academy of Sciences is a major force in China’s biomedical research field. Through this strategic cooperation with CAS’ wholly owned innovation and investment arm, HUYA will substantially widen our access to the frontier of pharmaceutical science and technology at CAS,” said Clement Gingras, HUYA’s Chief Technology Officer and Chief Operating Officer Asia, “and we expect more opportunities to globalize novel drugs discovered by the many talented scientists of CAS.

Mr. Zhonghua Li, Executive Vice President of CAS Innovation, also expressed his upbeat view: “Our national policy and CAS principles require us to commercialize our innovations in science and technology. To that end, our collaboration with HUYA is fully aligned with our organizational goals; we look forward to successful joint collaborations with HUYA.”

About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations have been established with innovators to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA’s lead immune-oncology product HBI-8000 is in registration trials in Japan for lymphoma and in clinical development in the U.S. for solid tumor indications. With the largest team of scientists working with Chinese innovators, HUYA develops promising drug candidates globally. For more information, please visit. www.huyabio.com

About Chinese Academy of Sciences Innovation and Investment Company
The Chinese Academy of Sciences Innovation and Investment Company, referred to as CAS Innovation, is a comprehensive market-oriented platform for transforming and industrializing science & technology (S&T) achievements. Wholly owned by the Chinese Academy of Sciences, CAS Innovation leverages the rich resources in S&T and talents of the CAS to build a nationwide network for incubating innovations from the CAS and for international collaboration on innovation. It is also committed to facilitating the development of strategic emerging industries and the upgrading of traditional industries, incubating innovative S&T enterprises, and advancing international technology transfer. Key activities of CAS Innovation include incubation of S&T business, transfer and transformation of S&T achievements, investments in S&T entrepreneurship, intellectual property operations, building S&T think tanks, and providing training to innovative start-ups. http://www.casii.ac.cn/

Clement Gingras CTO and COO Asia
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com

Yung-Chih Wang, PhD, MBA
VP, Corporate Development China
HUYA Bioscience International
+1.858.798.8818
ywang@huyabio.com

 

SOURCE HUYA Bioscience International

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

January 18, 2017 – 5:05 am

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ — HUYA Bioscience International, (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA is the first company to have recognized China’s potential as an important source of new innovative preclinical and clinical stage compounds. The company accelerates development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. In keeping with this strategic vision, HUYA has already established over one hundred collaborations with leading universities, research institutes, and science parks throughout China.

CAS Innovation is wholly owned by the Chinese Academy of Sciences. It is building a comprehensive platform for transforming and commercializing scientific and technological achievements, and fostering international collaborations. CAS Innovation has selected biomedicine as one of its core areas, positioning itself as a base for biopharmaceutical translational medicine, and targeting innovative R&D in the high-end segment of the industry value chain in order to push forward industrialization of China’s most innovative drugs.

Under this agreement, HUYA and CAS Innovation will collaborate to develop novel drugs discovered by CAS scientists. Biotech and pharmaceutical R&D organizations within the CAS Innovation platform will have access to HUYA’s international pharmaceutical expertise and networks as well as support from HUYA’s global team of experts. In turn, HUYA will have priority to evaluate certain research and development projects conducted by these CAS organizations and secure partnerships to further develop and commercialize these candidate therapeutics for global markets.

“The Chinese Academy of Sciences is a major force in China’s biomedical research field. Through this strategic cooperation with CAS’ wholly owned innovation and investment arm, HUYA will substantially widen our access to the frontier of pharmaceutical science and technology at CAS,” said Clement Gingras, HUYA’s Chief Technology Officer and Chief Operating Officer Asia, “and we expect more opportunities to globalize novel drugs discovered by the many talented scientists of CAS.

Mr. Zhonghua Li, Executive Vice President of CAS Innovation, also expressed his upbeat view: “Our national policy and CAS principles require us to commercialize our innovations in science and technology. To that end, our collaboration with HUYA is fully aligned with our organizational goals; we look forward to successful joint collaborations with HUYA.”

About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations have been established with innovators to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA’s lead immune-oncology product HBI-8000 is in registration trials in Japan for lymphoma and in clinical development in the U.S. for solid tumor indications. With the largest team of scientists working with Chinese innovators, HUYA develops promising drug candidates globally. For more information, please visit. www.huyabio.com

About Chinese Academy of Sciences Innovation and Investment Company
The Chinese Academy of Sciences Innovation and Investment Company, referred to as CAS Innovation, is a comprehensive market-oriented platform for transforming and industrializing science & technology (S&T) achievements. Wholly owned by the Chinese Academy of Sciences, CAS Innovation leverages the rich resources in S&T and talents of the CAS to build a nationwide network for incubating innovations from the CAS and for international collaboration on innovation. It is also committed to facilitating the development of strategic emerging industries and the upgrading of traditional industries, incubating innovative S&T enterprises, and advancing international technology transfer. Key activities of CAS Innovation include incubation of S&T business, transfer and transformation of S&T achievements, investments in S&T entrepreneurship, intellectual property operations, building S&T think tanks, and providing training to innovative start-ups. http://www.casii.ac.cn/

Clement Gingras CTO and COO Asia
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com

Yung-Chih Wang, PhD, MBA
VP, Corporate Development China
HUYA Bioscience International
+1.858.798.8818
ywang@huyabio.com

 

SOURCE HUYA Bioscience International

Medical Director – NEUROCRINE BIOSCIENCES – San Diego, CA

January 18, 2017 – 5:00 am

Minimum of 2 years ofexperience in Medical Affairs or related activities in a pharmaceutical(preferably), biotechnology company or consulting capacity….From Spirit Realty – Wed, 18 Jan 2017 13:00:19 GMT – View all San Diego jobs

Director – Research – NEUROCRINE BIOSCIENCES – San Diego, CA

January 18, 2017 – 5:00 am

Preferred candidates will have experience in innovativemodalities for interrogating therapeutic targets and experience in a biotechnology orpharmaceutical…From Spirit Realty – Wed, 18 Jan 2017 13:00:19 GMT – View all San Diego jobs

Invetech Announces Agreement with Erytech to Develop Scalable Automated Manufacturing System

January 18, 2017 – 5:00 am

New suite of customized equipment is intended to enable scalable, cost-effective GMP manufacturing of Erytech’s proprietary therapeutic product candidates based on its ERYCAPS platform

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ — Invetech, the leading developer of cGMP manufacturing solutions for cell and advanced therapies, has announced a collaboration agreement with Erytech Pharma, the French biopharmaceutical company developing “tumor starvation” treatments for acute leukemia and other oncology indications with unmet medical needs. Under the agreement, Invetech will develop systems to enable the commercial-scale manufacture of products based on Erytech’s proprietary ERYCAPS technology platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells and is designed to more effectively deliver therapeutics with reduced side effects.

“We are excited to support Erytech as they advance their novel therapeutic product candidates towards commercialization,” said Richard Grant, global vice president of cell therapy at Invetech. “With 15 years of experience in the development of clinical and commercial-scale manufacturing solutions for cell and advanced therapies, we believe we bring the depth of experience and creative technology solutions necessary to support Erytech’s expanding manufacturing needs at every stage of their growth.”

Invetech is developing GMP-compliant manufacturing equipment tailored to Erytech’s proprietary encapsulation technology. The manufacturing system will be designed to allow rapid capacity expansion to accommodate production volume needs for commercialization of Erytech’s product candidates following the receipt of the necessary regulatory approvals. The customized equipment will fully integrate with Erytech’s selected Manufacturing Execution System (MES) to seamlessly manage electronic patient batch records. The system will be designed to provide Erytech with an advanced capability for consistent, controlled product quality within the production process, highly configurable process control in development, and the flexibility to modify the system to address the manufacturing requirements of future product candidates based on Erytech’s ERYCAPS technology platform. 

“Our depth of knowledge in cell handling, scalability and manufacturing automation allows us to identify and develop the optimal streamlined manufacturing process. The solutions we will be developing for Erytech will support product consistency and efficacy, ensure regulatory compliance, and are anticipated to result in a lower cost of goods for Erytech,” said David Kneen, cell therapy program manager at Invetech. “This collaboration reflects Invetech’s expertise in multi-disciplinary system integration, and longstanding commitment to providing robust, innovative design solutions that address the challenges presented by cell and advanced therapy manufacture.”  

About Invetech

Invetech has created breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5,000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing and custom automation services. The company has experience in a broad range of market sectors including laboratory diagnostics, point of care diagnostics, life sciences, and cell and advanced therapy automated production systems. To learn more about Invetech, please visit http://www.invetech.us.

Invetech Media Contact:
Bill Berry
Berry & Company Public Relations
Phone: 212-253-8881
bberry@berrypr.com

 

SOURCE Invetech